{"organizations": [], "uuid": "68332753f90b19b79a4b2bf5fe2887d52cb0ccca", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-durect-announces-amendment-to-lice/brief-durect-announces-amendment-to-licensing-agreement-with-sandoz-idUSFWN1SG0U9", "country": "US", "domain_rank": 408, "title": "BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T15:05:00.000+03:00", "replies_count": 0, "uuid": "68332753f90b19b79a4b2bf5fe2887d52cb0ccca"}, "author": "", "url": "https://www.reuters.com/article/brief-durect-announces-amendment-to-lice/brief-durect-announces-amendment-to-licensing-agreement-with-sandoz-idUSFWN1SG0U9", "ord_in_thread": 0, "title": "BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz", "locations": [], "entities": {"persons": [{"name": "durect", "sentiment": "none"}], "locations": [], "organizations": [{"name": "sandoz", "sentiment": "negative"}, {"name": "sandoz reuters", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "durect corp", "sentiment": "none"}, {"name": "durect corp", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9, 2018 / 12:07 PM / in 10 minutes BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz Reuters Staff\nMay 9 (Reuters) - DURECT Corp:\n* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)\n* DURECT CORP - DURECT IS NOW ELIGIBLE FOR UP TO $30 MILLION IN MILESTONE PAYMENTS BASED ON NDA APPROVAL\n* DURECT CORP - EACH PARTY, PURSUANT TO AMENDMENT, IS ALSO PERMITTED TO DEVELOP OR COMMERCIALIZE COMPETING PRODUCTS\n* DURECT CORP - PURSUANT TO AMENDED AGREEMENT, DURECT REMAINS ELIGIBLE FOR UP TO AN ADDITIONAL $230 MILLION IN SALES-BASED MILESTONES\n* DURECT - PURSUANT TO AMENDED AGREEMENT, THERE IS NEW TERMINATION FEE PAYABLE TO DURECT IN EVENT THAT SANDOZ TERMINATES AGREEMENT FOR CONVENIENCE\n* DURECT CORP - AMENDMENT ALSO INCLUDES MODIFICATIONS TO DURECT’S DEVELOPMENT OBLIGATIONS AND TO BOTH PARTIES’ TERMINATION PROVISIONS\n* DURECT CORP - DURECT HAS RIGHT TO TERMINATE FOR CONVENIENCE PRIOR TO NDA APPROVAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-09T15:05:00.000+03:00", "crawled": "2018-05-09T15:21:09.004+03:00", "highlightTitle": ""}